It can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects

Can resist subtype I influenza virus and inhibit virus reproduction

It is an anti-allergic drug that can relieve symptoms such as runny nose, nasal congestion, and sneezing.

It has antipyretic and sedative effects

It is a central nervous system stimulant that can enhance the antipyretic and analgesic effects of acetaminophen and reduce central nervous system inhibitory effects such as drowsiness and dizziness caused by other drugs.

Glucocorticoids, which have anti-inflammatory and anti-allergic effects

It has the effects of promoting local circulation and mildly anti-inflammatory, analgesic and antipruritic

It has the effects of promoting local circulation and mildly anti-inflammatory, analgesic and antipruritic

It has no antibacterial activity in vitro. After oral administration, it is hydrolyzed into chloramphenicol by pancreatic lipase in the duodenum and absorbed into the body to exert its antibacterial effect. It has antibacterial activity against aerobic Gram-negative bacteria and Gram-positive bacteria, anaerobic bacteria, Rickettsia, spirochetes and Chlamydia. It has bactericidal effects on influenza bacilli, Streptococcus pneumoniae and Neisseria meningitidis; it only has antibacterial effects on anaerobic bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Group B soluble Streptococci, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella typhi, Salmonella paratyphi, Shigella, Bacteroides fragilis, etc. Pseudomonas aeruginosa, Acinetobacter, Enterobacter, Serratia marcescens, indole-positive Proteus, methicillin-resistant Staphylococcus and Enterococcus are usually resistant to chloramphenicol. Chloramphenicol is fat-soluble and enters the bacterial cells by diffusion, binds to the 50S subunit of the bacterial ribosome, inhibits the formation of peptide chains, and thus prevents protein synthesis.

This product is a synthetic antibacterial anti-tuberculosis drug that can penetrate into mycobacteria to interfere with RNA synthesis, thereby inhibiting bacterial reproduction. It is only effective against mycobacteria in the growth and reproduction period. So far, no cross-resistance has been found between this product and other anti-tuberculosis drugs.

This product is a hypoglycemic drug. It can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes, and HbAlc can be reduced by 1% to 2%. The mechanism of lowering blood sugar may be: 1. Increasing the sensitivity of peripheral tissues to insulin and increasing insulin-mediated glucose utilization; 2. Increasing the utilization of glucose by non-insulin-dependent tissues, such as the brain, blood cells, renal medulla, intestines, skin, etc.; 3. Inhibiting hepatic gluconeogenesis and reducing hepatic glucose output; 4. Inhibiting intestinal wall cells from taking up glucose; 5. Inhibiting the biosynthesis and storage of cholesterol and reducing blood triglyceride and total cholesterol levels.